Nektar Concludes Enrollment In Phase 2 Clinical Trial For NKTR-102

Nektar Therapeutics (Nektar) has completed patient enrollment ahead of schedule in its phase 2 clinical study of NKTR-102 in platinum-resistant ovarian cancer. NKTR-102 is company’s investigational proprietary compound currently being evaluated in phase 2 clinical development in ovarian, breast and colorectal cancers.

NKTR-102 is a novel prodrug of irinotecan that was designed using Nektar’s proprietary small molecule advanced polymer conjugate technology platform.

The phase 2 study has a two-stage design and is evaluating two dose regimens (once every 14 days and once every 21 days) of single-agent NKTR-102 in women with platinum-resistant ovarian cancer.

Reportedly, the study enrolled a total of 70 women whose tumors do not respond well to platinum-based chemotherapy, with 40 patients enrolled in the first stage and 30 patients enrolled in the second stage. The majority of the patients enrolled in the trial continue to receive treatment with NKTR-102.

Lorianne Masuoka, chief medical officer at Nektar, said: “We have completed enrollment in the second stage of our study in an unusually short period of time, which reflects the enthusiasm of the investigators working with NKTR-102 in this particularly challenging cancer. The majority of women in the NKTR-102 trial continue on therapy and we are looking forward to announcing preliminary response data from the study in the coming months. We are extremely excited about the potential of NKTR-102 to offer a valuable and promising new treatment option for women with platinum-resistant ovarian cancer.”